Maria Aleshin, MD
Dermatology · Stanford, CANPI 1861810558
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,250 of the $26,541 with a category attached, or 83.8%. Novartis accounts for 96.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $9,772, more than ten times the $97 reported in 2019. Among dermatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $884.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$26K
- AbbVie$625
- Boehringer Ingelheim$116
- E.r. Squibb & Sons, L.L.C.$72
Across 3 payments — averaging $9656.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$29K
What the payments were for
- Consulting fees$22,25084%
- Travel & lodging$3,24112%
- Food & beverage$1,0384%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 23 | $25,727 |
| AbbVie(2 entities) | 4 | $625 |
| Boehringer Ingelheim | 1 | $116 |
| E.r. Squibb & Sons, L.L.C. | 2 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,541 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 24 | $442,522 |
| Cosentyx Unoready PenSecukinumab | 17 | $283,254 |
| Dupixent PenDupilumab | 59 | $209,343 |
| Dupixent SyringeDupilumab | 15 | $63,808 |
| Clobetasol Propionate | 57 | $3,979 |
| Clindamycin Phosphate | 39 | $1,677 |
| Tacrolimus | 15 | $1,136 |
| Ketoconazole | 62 | $909 |
| Metronidazole | 15 | $890 |
| Triamcinolone Acetonide | 70 | $683 |
| Fluocinonide | 21 | $673 |
| Metformin Hcl | 18 | $657 |
| Doxycycline Hyclate | 24 | $555 |
| Mupirocin | 40 | $316 |
| Hydrocortisone | 62 | $267 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Stanford
- Matthew LewisStanford$442K
- Justin KoStanford$237K
- David FiorentinoStanford$166K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.